NCT00153179View on ClinicalTrials.gov

Free Fatty Acids and Vascular Function in Subjects With Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

September 30, 2005

Primary Completion Date

December 31, 2011

Study Completion Date

March 31, 2013

Conditions
Type 2 Diabetes Mellitus
Interventions
DRUG

acipimox

subjects will receive acipimox 250 mg orally every 6 hours (or matching placebo) for 7 days, including a dose at 6am on the morning of the study testing visit

DRUG

placebo

matching placebo

Trial Locations (1)

02115

Brigham & Women's Hospital, Boston

All Listed Sponsors
lead

Brigham and Women's Hospital

OTHER

NCT00153179 - Free Fatty Acids and Vascular Function in Subjects With Diabetes | Biotech Hunter | Biotech Hunter